{"url_path":"/sec/inbp/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-015899-index.html","accession_number":"0001437749-26-015899","cik":"0001016504","ticker":"INBP","issuer_name":"INTEGRATED BIOPHARMA INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-015899-index.html","primary_entity_key":"0001016504","primary_entity_name":"INTEGRATED BIOPHARMA INC"},"word_count":228,"has_tables":true,"body_markdown":"**Item 6. EXHIBITS**\n\n \n\n**(a)**         **Exhibits**\n\n \n\n**Exhibit**\n\n**Number**\n\n31.1\n\n[Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.](ex_936597.htm)\n\n31.2\n\n[Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.](ex_936598.htm)\n\n32.1\n\n[Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.](ex_936599.htm)\n\n32.2\n\n[Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.](ex_936600.htm)\n\n101.INS***\n\nInline XBRL Instance\n\nFurnished herewith\n\n101.SCH***\n\nInline XBRL Taxonomy Extension Schema\n\nFurnished herewith\n\n101.CAL***\n\nInline XBRL Taxonomy Extension Calculation\n\nFurnished herewith\n\n101.DEF***\n\nInline XBRL Taxonomy Extension Definition\n\nFurnished herewith\n\n101.LAB***\n\nInline XBRL Taxonomy Extension Labels\n\nFurnished herewith\n\n101.PRE***\n\nInline XBRL Taxonomy Extension Presentation\n\nFurnished herewith\n\n104\n\nCover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)\n\n25\n\n \n\n \n\n**SIGNATURES**\n\n \n\n \n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n**INTEGRATED BIOPHARMA, INC.**\n\n \n\n \n\nDate:         May 8, 2026\nBy: /s/ *Christina Kay*\n\n \nChristina Kay,\n\n \nCo-Chief Executive Officer\n\n \n \n\nDate:         May 8, 2026 \nBy: /s/ *Riva Sheppard*\n\n \nRiva Sheppard,\n\n \nCo-Chief Executive Officer\n\n \n \n\n \nBy: /s/ *Dina L. Masi*\n\nDate:         May 8, 2026 \nDina L. Masi,\n\n \nChief Financial Officer & Senior Vice President\n\n \n \n\n \n \n\n \n\n \n\n         \n\n                 \n\n \n\n \n\n26"}